RJA
KRYS icon

Raymond James & Associates’s Krystal Biotech KRYS Stock Holding History

Raymond James & Associates’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$521K Buy
2,861
+32
+1% +$6.17K ﹤0.01% 3087
2024
Q2 		$520K Buy
+2,829
New +$475K ﹤0.01% 3057

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's KRYS Position: Q3 2024 in Review

Raymond James & Associates increased its Krystal Biotech (KRYS) stake by 1.1% in Q3 2024, buying an estimated $6.17K and bringing the position to 2,861 shares worth $521K. The position accounts for ﹤0.01% of the portfolio, ranked #3087.

Raymond James & Associates first reported a position in KRYS in Q2 2024 and has held it in 2 quarters since. 283 funds tracked by Wall St. Rank hold KRYS as of Q3 2024.

  • Raymond James & Associates held 2,861 shares of Krystal Biotech worth $521K as of Q3 2024.
  • Raymond James & Associates bought 32 Krystal Biotech shares in Q3 2024, an estimated $6.17K.
  • Krystal Biotech made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3087 holding.
  • Raymond James & Associates first reported a position in Krystal Biotech in Q2 2024 and has held it in 2 quarters since.
  • 283 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.